Most people with MGUS will never develop multiple myeloma. The overall risk of progression is roughly 1% per year, and that risk persists for as long as you have the condition. But certain features of your MGUS can push that risk much higher or lower, and understanding those factors is the key to knowing where you stand.
The Overall Risk of Progression
MGUS progresses to multiple myeloma or a related blood cancer at an average rate of about 1% per year. That means after 20 years, roughly 20% of people with MGUS will have developed a malignancy. The other 80% will not. This is a lifelong risk that doesn’t go away over time, which is why ongoing monitoring matters, but it also means the odds are solidly in your favor in any given year.
Not everyone faces the same 1% annual risk, though. A risk model developed at the Mayo Clinic divides MGUS into categories based on three measurable factors in your blood work. Where you fall on that scale dramatically changes your outlook.
What Determines Your Risk Level
Three specific lab findings predict whether MGUS is more or less likely to progress:
- The amount of abnormal protein in your blood. A monoclonal protein (M-protein) level above 1.5 g/dL is a risk factor.
- The type of abnormal protein. MGUS involving non-IgG types of antibody (such as IgA or IgM) carries higher risk than the more common IgG type.
- An abnormal free light chain ratio. Light chains are small pieces of antibody proteins. A ratio outside the normal range of 0.26 to 1.65 signals that the abnormal clone of cells is producing disproportionately more of one type.
If you have none of these three risk factors, your 20-year risk of progression is about 5%. With one factor, it’s still around 5%. With two factors present, the risk climbs to about 21% over 20 years. If all three are present, the 20-year risk reaches roughly 58%. That’s a massive range, and it’s why two people with MGUS can have very different conversations with their doctors about what to expect.
The Path From MGUS to Myeloma
MGUS doesn’t typically jump straight to active multiple myeloma. There’s usually an intermediate stage called smoldering multiple myeloma (SMM). The boundaries between these stages are defined by how many abnormal plasma cells are in your bone marrow and how much abnormal protein is circulating in your blood.
With MGUS, the abnormal plasma cells make up less than 10% of bone marrow cells, and the M-protein stays below 3 g/dL. Once bone marrow plasma cells reach 10% or more, or the M-protein hits 3 g/dL or higher, the diagnosis shifts to smoldering myeloma. Smoldering myeloma is still not causing organ damage, but the abnormal cell population has grown significantly.
Active multiple myeloma is diagnosed when those abnormal cells start causing real harm to the body, or when certain biomarkers cross thresholds that signal damage is imminent. The international criteria use two sets of markers to define this transition. The first set, known by the acronym CRAB, captures organ damage: high calcium levels, kidney failure, anemia, and bone lesions. The second set identifies biological red lines: bone marrow plasma cells reaching 60% or higher, a free light chain ratio of 100 or greater, or more than one focal lesion on MRI. Crossing any of these thresholds means the disease needs treatment.
What Drives the Transformation
MGUS cells already carry many of the same genetic abnormalities found in full-blown myeloma cells. What keeps them from becoming cancerous isn’t necessarily a lack of dangerous mutations. It’s the bone marrow environment holding them in check. Immune cells, bone cells, and the surrounding tissue all play a role in suppressing the growth of the abnormal clone.
Progression happens when that balance breaks down. The immune system’s ability to control the clone weakens: T cells, natural killer cells, and other immune effectors lose their ability to keep the abnormal population in check. At the same time, the abnormal cells can acquire additional genetic changes, particularly activation of a gene called c-myc, that accelerate their growth. Certain chromosomal abnormalities, like deletions on chromosome 17 or gains on chromosome 1, correlate with higher risk of transformation.
The bone marrow itself changes during progression. Cells that normally build new bone lose function, while cells that break down bone become overactive. Myeloma cells and bone-destroying cells feed each other in a loop: the cancer promotes bone breakdown, and the bone breakdown in turn supports cancer cell growth and survival. Supportive cells in the bone marrow begin secreting growth factors and releasing tiny packages of genetic material (exosomes) that further fuel the expanding clone. In essence, the neighborhood changes from one that restrains the abnormal cells to one that actively supports them.
Warning Signs That Suggest Progression
MGUS itself causes no symptoms. The signs that something has changed come from the organ damage that defines active myeloma. Bone disease is the most common presenting problem, affecting about 68% of people at diagnosis. This typically shows up as persistent bone pain, especially in the back or ribs, or as fractures from minimal trauma. Anemia is the second most common issue (57% of cases), causing fatigue, weakness, and shortness of breath. Kidney problems occur in about 29% of cases, and high calcium, though less common at 6%, can cause excessive thirst, frequent urination, constipation, and confusion.
Any of these symptoms in someone with known MGUS should prompt immediate evaluation. A rising M-protein level on routine blood work, even before symptoms appear, can also signal that the condition is moving toward smoldering myeloma or beyond.
How Monitoring Works
Because progression can happen at any point, MGUS requires lifelong surveillance. The monitoring schedule depends on your risk level. For low-risk MGUS, the standard approach is a blood test (serum protein electrophoresis) at six months after diagnosis, then every two to three years if results remain stable. For higher-risk categories, blood work typically happens at six months and then annually for life, including a complete blood count and kidney function tests alongside the protein measurements.
The goal of monitoring isn’t to catch the moment MGUS “becomes” myeloma. It’s to catch the intermediate stages, particularly smoldering myeloma, before organ damage occurs. A steadily rising M-protein, a worsening light chain ratio, or dropping blood counts are the signals your doctor is watching for. If your numbers hold steady year after year, that’s reassuring. MGUS that remains stable for many years still carries the same annual risk going forward, but stable labs mean the clone isn’t actively expanding at that moment.